Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Colorcon
Moodys
Merck
Dow

Last Updated: November 29, 2021

DrugPatentWatch Database Preview

Claims for Patent: 6,403,104

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 6,403,104
Title: Hapten-conjugated mammalian cells and methods of making and using thereof
Abstract:The present invention is directed to mammalian cells conjugated to a hapten and methods of making and using thereof. Conjugating hapten to mammalian cells is a useful way of preventing cells from growing and may be used in the place of any conventional treatment, for example, irradiation. Thus, the invention relates to mammalian cells in general, for example human cells, which cells are in substantially no growth phase and a method of placing the cells in a substantially no growth phase by conjugating them to a hapten. The invention is further directed to compositions containing hapten-modified tumor cells and extracts and methods of treating cancer by administering a therapeutically effective amount of a composition containing a tumor cell or tumor cell extract to a subject in need of such treatment. The tumor cells and extracts of the invention and compositions thereof are capable of eliciting T lymphocytes that have a property of infiltrating a mammalian tumor, eliciting an inflammatory immune response to a mammalian tumor, eliciting a delayed-type hypersensitivity response to a mammalian tumor and/or stimulating T lymphocytes in vitro. The invention also relates to an effective vaccination schedule useful for inducing an antitumor response in a mammalian patient suffering from cancer by inducing at least one of the following: tumor necrosis, tumor regression, tumor inflammation, tumor infiltration by activated T lymphocytes, delayed-type hypersensitivity response, and prolongation of patient survival. Furthermore, the invention relates to an improved, simplified and economical method for preparing the hapten-conjugated tumor cells for administration as a vaccine by eliminating a separate step of treating cells (by irradiation, for example) to place them in a no growth phase.
Inventor(s): Berd; David (Wyncote, PA)
Assignee: Thomas Jefferson University (Philadelphia, PA)
Application Number:09/526,395
Patent Claims:1. A method for inducing an anti-tumor response in a human patient suffering from a tumor, which method comprises administering to said patient a composition comprising a therapeutically effective amount of tumor cells that are:

(i) conjugated to a hapten;

(ii) of the same tumor type as the patient's tumor, and

(iii) not allogeneic to said patient;

wherein hapten conjugation renders the tumor cells incapable of growing in the body of the patient, and wherein said tumor cells are not separately treated to render them incapable of growing in the body of the patient.

2. The method of claim 1 wherein said tumor cells are not irradiated.

3. The method of claim 1, wherein said administration is repeated at weekly intervals.

4. The method of claim 1, wherein said composition is administered for at least three times.

5. The method of claim 1, wherein said composition is administered for at least six times.

6. The method of claim 1 further comprising administering a therapeutically effective amount of cyclophosphamide prior to administration of said composition.

7. The method of claim 6, wherein cyclophosphamide is administered only prior to the first administration of said composition.

8. The method of claim 6 wherein said therapeutically effective amount of cyclophosphamide comprises administering a dose of about 300 mg/M.sup.2 of cyclophosphamide.

9. The method of claim 1 wherein said tumor cells are selected from the group consisting of melanoma, lung, colon, breast, kidney, prostate, ovarian and leukemia tumor cells.

10. The method of claim 9, wherein said tumor cells are melanoma tumor cells.

11. The method of claim 1 wherein said hapten is selected from the group consisting of dinitrophenyl, trinitrophenyl, N-iodoacetyl-N'-(5-sulfonic-1-naphthyl)ethylene diamine, trinitrobenzenesulfonic acid, fluorescein isothiocyanate, arsenic acid benzene isothiocyanate, trinitrobenzenesulfonic acid, sulfanilic acid, arsanilic acid, dinitrobenzene-S-mustard and combinations thereof.

12. The method of claim 11 wherein said hapten is dinitrophenyl.

13. The method of claim 1 wherein said composition is administered with an adjuvant.

14. The method of claim 13 wherein said adjuvant is selected from the group consisting of Bacillus Calmette-Guerin, QS-21, detoxified endotoxin and a cytokine.

15. The method of claim 1 further comprising sensitizing the patient with a therapeutically effective amount of the hapten prior to administering said composition.

16. The method of claim 1 wherein said human is not sensitized to said hapten prior to administration of said composition.

17. The method of claim 1 wherein said composition comprises a maximum of about 7.5.times.10.sup.6 tumor cells per dose.

18. The method of claim 1 wherein said anti-tumor response is at least one of the following: tumor necrosis, tumor regression, tumor inflammation, tumor infiltration by activated T lymphocytes, stable disease and prolongation of patient survival.

19. A composition for inducing an anti-tumor response in a human patient suffering from a tumor comprising a therapeutically effective amount of tumor cells that are:

(i) conjugated to a hapten;

(ii) of the same tumor type as the patient's tumor, and

(iii) not allogeneic to said patient;

wherein hapten conjugation renders the tumor cells incapable of growing in the body of the patient, and wherein said tumor cells are not irradiated prior to administration to the patient.

20. The composition of claim 19 comprising a maximum of about 7.5.times.10.sup.6 tumor cells.

21. The composition of claim 19 wherein said tumor cells are selected from the group consisting of melanoma, lung, colon, breast, kidney, prostate, ovarian and leukemia tumor cells.

22. The composition of claim 19 wherein said hapten is selected from the group consisting of dinitrophenyl, trinitrophenyl, N-iodoacetyl-N'-(5-sulfonic 1-naphthyl)ethylene diamine, trinitrobenzenesulfonic acid, fluorescein isothiocyanate, arsenic acid benzene isothiocyanate, trinitrobenzenesulfonic acid, sulfanilic acid, arsanilic acid, dinitrobenzene-S-mustard and combinations thereof.

23. The composition of claim 22 wherein said hapten is dinitrophenyl.

24. The composition of claim 19 further comprising an adjuvant.

25. The composition of claim 24 wherein said adjuvant is selected from the group consisting of Bacillus Calmette-Guerin, QS-21, detoxified endotoxin and a cytokine.

26. A method for rendering a human tumor cell incapable of growing, which method comprises the step of conjugating the human tumor cell to a hapten in vitro, wherein hapten conjugation renders said human tumor cell incapable of growing, and wherein said human tumor cell is not separately treated to render it incapable of growing.

27. The method of claim 26, wherein the human tumor cell is not irradiated.

28. The method of claim 26, wherein said human tumor cell is selected from the group consisting of a melanoma, lung, colon, breast, kidney, prostate, ovarian and leukemia tumor cell.

29. The method of claim 26, wherein said human tumor cell is a human melanoma cell.

30. The method of claim 26, wherein said hapten is selected from the group consisting of dinitrophenyl, trinitrophenyl, N-iodoacetyl-N'-(5-sulfonic 1-naphthyl)ethylene diamine, trinitrobenzenesulfonic acid, fluorescein isothiocyanate, arsenic acid benzene isothiocyanate, trinitrobenzenesulfonic acid, sulfanilic acid, arsanilic acid, dinitrobenzene-S-mustard and combinations thereof.

31. The method of claim 30, wherein said hapten is dinitrophenyl.

32. The method of claim 30, wherein said hapten is sulfanilic acid.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
McKesson
Express Scripts
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.